Breast cancer - metastatic breast cancer
The PBS subsidises lapatinib, pertuzumab, trastuzumab and trastuzumab emtansine for patients with metastatic breast cancer.
Treatment with lapatinib, pertuzumab, trastuzumab subcutaneous (s.c) and intravenous (i.v.) and trastuzumab emtansine can be subsidised through the Pharmaceutical Benefits Scheme (PBS) under the National Health Act 1953, Section 85 and Section 100 for a patient with human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer.
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits outlines the restrictions for prescribing lapatinib, pertuzumab, trastuzumab and trastuzumab emtansine.
Section 100 arrangements
This item is available to a patient who is attending:
- an approved private hospital
- a public participating hospital, or
- a public hospital
and is either a
- day admitted patient
- non-admitted patient, or
- patient on discharge
These items aren’t available as a PBS benefit for hospital in-patients. You need to include the hospital name and provider number on the authority application form.
Make all initial applications for authority approval to prescribe lapatinib, pertuzumab, trastuzumab and trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer in writing and:
All applications must include the completed:
- authority prescription form(s)
- Metastatic breast cancer Initial PBS authority application supporting information form
- relevant attachments
Continuing, changing or recommencing treatment
To make continuing applications for treatment with pertuzumab, trastuzumab and trastuzumab emtansine call the PBS Complex Drugs Programs enquiry line.
Continuing treatment with lapatinib is Authority Required (Streamlined) and does not require prior authority approval from the Department of Human Services.
Call the PBS Complex Drugs Programs enquiry line for more information.
Page last updated: 22 February 2019